Indolent Lymphoma
News
Bendamustine-based chemotherapy induces high CR rate in relapsed HL
Key clinical point: Bendamustine in combination chemotherapy produces high response rates in relapsed refractory Hodgkin lymphoma (HL). Major...
News
Adding obinutuzumab to bendamustine boosts progression-free survival in rituximab-refractory indolent non-Hodgkin lymphoma
Key clinical point: Obinutuzumab is an option when patients with indolent non-Hodgkin lymphoma relapse or don’t achieve adequate disease control...
News
Follicular lymphoma with histologic transformation may merit ASCT
Key clinical point: Histologic transformation of follicular lymphoma tends to occur early and may merit intensive salvage with autologous stem...
Conference Coverage
Brentuximab vedotin boosted PET-negative rate in Hodgkin
Key clinical point: Brentuximab vedotin appears to eradicate residual disease after induction chemotherapy in a small study of patients with...
News
Enzastaurin flops as maintenance in treated DLBCL
Key clinical point: The experimental agent enzastaurin was no better than placebo as maintenance therapy in patients who had achieved a complete...
News
Epstein-Barr virus DNA in plasma reliably detects EBV-positive lymphoproliferative disorders
Key clinical point: Epstein-Barr virus DNA was a more specific indicator of EBV+ diseases when detected in plasma, as opposed to peripheral blood...
News
Low transformation rate in nodular lymphocyte–predominant Hodgkin lymphoma
Key clinical point: The risk of transformation to diffuse large B-cell lymphoma is low in patients with nodular lymphocyte–predominant Hodgkin...
News
New single-tube assay detects one CLL cell in 1 million leukocytes
Key clinical point: Chronic lymphocytic leukemia cells can be identified at levels as low as 0.0010% with a newly developed and validated single-...
News
VP Biden to AACR: Help me help you
Strengthening teamwork among researchers, sharing data, and realigning incentives for scientific breakthroughs are top strategies to advance...
News
In newly diagnosed CLL, mutation tests are advised
News
FDG-PET guides need for eBEACOPP in advanced Hodgkin’s
Key clinical point: Using FDG-PET imaging to gauge treatment response after the first two rounds of ABVD therapy helps to determine which patients...